Home LiteratureArticle Details
PMID: 20604938 Published · epublish English Journal Article

Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.

BMC genomics ·Vol. 11 ·2010-07-06 ·Pages 419

Kumar R, Blakemore SJ, Ellis CE, Petricoin EF, Pratt D, Macoritto M, Matthews AL, Loureiro JJ, Elliston K

Abstract

Inappropriate activation of AKT signaling is a relatively common occurrence in human tumors, and can be caused by activation of components of, or by loss or decreased activity of inhibitors of, this signaling pathway. A novel, pan AKT kinase inhibitor, GSK690693, was developed in order to interfere with the inappropriate AKT signaling seen in these human malignancies. Causal network modeling is a systematic computational analysis that identifies upstream changes in gene regulation that can serve as explanations for observed changes in gene expression. In this study, causal network modeling is employed to elucidate mechanisms of action of GSK690693 that contribute to its observed biological effects. The mechanism of action of GSK690693 was evaluated in multiple human tumor cell lines from different tissues in 2-D cultures and xenografts using RNA expression and phosphoproteomics data. Understanding the molecular mechanism of action of novel targeted agents can enhance our understanding of various biological processes regulated by the intended target and facilitate their clinical development. Causal network modeling on transcriptomic and proteomic data identified molecular networks that are comprised of activated or inhibited mechanisms that could explain observed changes in the sensitive cell lines treated with GSK690693. Four networks common to all cell lines and xenografts tested were identified linking GSK690693 inhibition of AKT kinase activity to decreased proliferation. These networks included increased RB1 activity, decreased MYC activity, decreased TFRC activity, and increased FOXO1/FOXO3 activity. AKT is involved in regulating both cell proliferation and apoptotic pathways; however, the primary effect with GSK690693 appears to be anti-proliferative in the cell lines and xenografts evaluated. Furthermore, these results indicate that anti-proliferative responses to GSK690693 in either 2-D culture or xenograft models may share common mechanisms within and across sensitive cell lines.

MeSH Terms
Animals Antigens, CD/genetics,metabolism Antineoplastic Agents/pharmacology Cell Cycle/drug effects Cell Line, Tumor Cell Proliferation/drug effects Cell Survival/drug effects Female Forkhead Box Protein O1 Forkhead Box Protein O3 Forkhead Transcription Factors/genetics,metabolism Gene Expression Profiling Humans Mice Models, Biological Oxadiazoles/pharmacology Phosphoproteins/metabolism Protein Kinase Inhibitors/pharmacology Proteome/genetics,metabolism Proto-Oncogene Proteins c-akt/antagonists & inhibitors,genetics,metabolism Proto-Oncogene Proteins c-myc/genetics,metabolism Receptors, Transferrin/genetics,metabolism Retinoblastoma Protein/metabolism Transcription, Genetic/drug effects Xenograft Model Antitumor Assays
Chemicals
Antigens, CD Antineoplastic Agents CD71 antigen FOXO1 protein, human FOXO3 protein, human Forkhead Box Protein O1 Forkhead Box Protein O3 Forkhead Transcription Factors GSK690693 MYC protein, human Oxadiazoles Phosphoproteins Protein Kinase Inhibitors Proteome Proto-Oncogene Proteins c-myc Receptors, Transferrin Retinoblastoma Protein Proto-Oncogene Proteins c-akt
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Kumar Rakesh
Oncology Biology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. [email protected]
Blakemore Stephen J
Ellis Catherine E
Petricoin Emanuel F
Pratt Dexter
Macoritto Michael
Matthews Andrea L
Loureiro Joseph J
Elliston Keith
References (42)
42 references, click to expand
  1. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.
    Mol Cell Biol. 1998 Feb;18(2):753-61 PMID: 9447971
  2. Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.
    Mol Cell Biol. 2007 Jul;27(13):4917-30 PMID: 17452451
  3. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?
    Nat Rev Cancer. 2004 Dec;4(12):948-55 PMID: 15573116
  4. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.
    Nat Cell Biol. 2007 Mar;9(3):316-23 PMID: 17277771
  5. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.
    Cell. 1999 Mar 19;96(6):857-68 PMID: 10102273
  6. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.
    Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15195-200 PMID: 16210249
  7. Activation of AKT kinases in cancer: implications for therapeutic targeting.
    Adv Cancer Res. 2005;94:29-86 PMID: 16095999
  8. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model.
    Hum Mol Genet. 2001 Mar 15;10(6):599-604 PMID: 11230179
  9. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake.
    Mol Biol Cell. 2002 Jul;13(7):2276-88 PMID: 12134068
  10. TOR, a central controller of cell growth.
    Cell. 2000 Oct 13;103(2):253-62 PMID: 11057898
  11. The Mad side of the Max network: antagonizing the function of Myc and more.
    Curr Top Microbiol Immunol. 2006;302:63-122 PMID: 16620026
  12. Rb-mediated chromatin structure regulation and transcriptional repression.
    Oncogene. 2001 May 28;20(24):3134-8 PMID: 11420730
  13. Novel targets of Akt, p21(Cipl/WAF1), and MDM2.
    Semin Oncol. 2002 Jun;29(3 Suppl 11):62-70 PMID: 12138399
  14. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Cancer Res. 2008 Apr 1;68(7):2366-74 PMID: 18381444
  15. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.
    Nat Med. 2002 Oct;8(10):1153-60 PMID: 12244302
  16. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins.
    EMBO J. 2004 Jul 21;23(14):2830-40 PMID: 15241468
  17. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines.
    Blood. 2009 Feb 19;113(8):1723-9 PMID: 19064730
  18. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.
    Mol Cell Biol. 2006 Mar;26(6):2373-86 PMID: 16508012
  19. The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma.
    Toxicol Sci. 2010 Jan;113(1):254-66 PMID: 19812364
  20. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue.
    Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4279-84 PMID: 10760294
  21. Mutation analysis of PTEN/MMAC 1 in sporadic thyroid tumors.
    Kaohsiung J Med Sci. 2000 Jan;16(1):9-12 PMID: 10741010
  22. Ras, PI(3)K and mTOR signalling controls tumour cell growth.
    Nature. 2006 May 25;441(7092):424-30 PMID: 16724053
  23. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis.
    Curr Mol Med. 2006 Nov;6(7):739-48 PMID: 17100600
  24. Transferrin receptors in human tissues: their distribution and possible clinical relevance.
    J Clin Pathol. 1983 May;36(5):539-45 PMID: 6302135
  25. The Myc oncoprotein as a therapeutic target for human cancer.
    Semin Cancer Biol. 2006 Aug;16(4):318-30 PMID: 16934487
  26. Exploiting the PI3K/AKT pathway for cancer drug discovery.
    Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 PMID: 16341064
  27. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
    Cell Signal. 2006 Dec;18(12):2262-71 PMID: 16839745
  28. Iron chelators as therapeutic agents for the treatment of cancer.
    Crit Rev Oncol Hematol. 2002 Jun;42(3):267-81 PMID: 12050019
  29. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603 PMID: 11504915
  30. Role of translocation in the activation and function of protein kinase B.
    J Biol Chem. 1997 Dec 12;272(50):31515-24 PMID: 9395488
  31. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo.
    BMC Syst Biol. 2009 Mar 10;3:31 PMID: 19284563
  32. Overexpression of Akt1 upregulates glycogen synthase activity and phosphorylation of mTOR in IRS-1 knockdown HepG2 cells.
    J Cell Biochem. 2008 Apr 1;103(5):1424-37 PMID: 17721885
  33. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.
    Nat Med. 2002 Oct;8(10):1136-44 PMID: 12244303
  34. The Akt/PKB pathway: molecular target for cancer drug discovery.
    Oncogene. 2005 Nov 14;24(50):7482-92 PMID: 16288295
  35. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.
    Clin Cancer Res. 2010 Jan 15;16(2):486-96 PMID: 20075391
  36. Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide.
    J Clin Invest. 1983 Oct;72(4):1314-25 PMID: 6313760
  37. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91 PMID: 15028555
  38. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.
    Cell Cycle. 2003 Jul-Aug;2(4):339-45 PMID: 12851486
  39. Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors.
    Circ Res. 2008 Mar 28;102(6):686-94 PMID: 18218983
  40. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
    Nature. 2007 Jul 26;448(7152):439-44 PMID: 17611497
  41. 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport.
    J Cell Biol. 2002 Mar 4;156(5):817-28 PMID: 11864996
  42. The transferrin receptor: a key function in iron metabolism.
    Schweiz Med Wochenschr. 1989 Sep 30;119(39):1319-26 PMID: 2678449
Article Info
Journal
BMC genomics
Abbr.
BMC Genomics
ISSN
1471-2164
Published
2010-07-06
Epub
2010-00-06
Pages
419
Language
English
Region
England
NLM ID
100965258
PMCID
PMC2996947
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]